AbbVie Inc. has formally denied media reports that it is in talks to acquire Revolution Medicines, Inc., pushing back against a Wall Street Journal story that said the companies were in advanced discussions over a potential takeover.
In a statement emailed to Reuters late Tuesday, AbbVie said “the company is not in discussions with Revolution Medicines”, directly contradicting the report. Revolution Medicines separately reiterated its long-standing policy of not commenting on market rumors or speculation.
Market Reaction: Sharp Reversal After Denial
The denial triggered an immediate reversal in after-hours trading:
- Revolution Medicines (RVMD) fell 11.5% in extended trading
- The stock had closed nearly 30% higher earlier in the session on takeover speculation
- AbbVie (ABBV) slipped about 1% after hours, after ending the regular session up 4%
Such swings are typical when takeover rumors inflate biotech valuations, particularly when the rumored buyer is a large pharmaceutical company with a history of major acquisitions.
Why the Rumour Moved Markets So Strongly
The Wall Street Journal report did not specify a deal price, but pointed to Revolution Medicines’ market capitalization of roughly $15.4 billion as of January 6, 2026. Analysts cited in the report suggested that, with a standard biotech acquisition premium, the company could have been valued at $20 billion or more.
That valuation range explains the outsized rally in Revolution’s shares before AbbVie’s denial.
Strategic Context: Why AbbVie Was Linked
AbbVie has been actively reshaping its oncology pipeline, especially as it works to offset long-term revenue pressure from the eventual erosion of Humira exclusivity. Revolution Medicines is viewed as a high-value oncology innovator, focused on precision cancer drugs targeting RAS-driven tumors, an area of strong industry interest.
Even without confirmed talks, the strategic logic behind the rumor was considered plausible by investors, helping fuel speculation.
What the Denial Actually Means
Importantly, AbbVie’s statement only addressed current discussions. In M&A terms, this means:
- There are no active negotiations at present, according to AbbVie
- It does not necessarily rule out future interest, partnerships, or a renewed approach
- Revolution Medicines remains an independent company for now
Such carefully worded denials are common and often aim to cool short-term market volatility rather than comment on long-term strategy.
Bottom Line for Investors
- The reported talks are not happening, per AbbVie
- The stock surge in Revolution Medicines was driven by speculation, not confirmation
- Volatility reflects continued takeover appeal of late-stage oncology assets
- Both companies are likely to remain under investor scrutiny in the near term
Source – AbbVie Denies Media Reports of Talks to Buy Revolution Medicines
